Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ArriVent BioPharma, Inc. (AVBP)

ArriVent Publishes Firmonertinib Phase 1b Results in Cancer Cell for PACC-Mutant Lung Cancer

Neutral Impact 2 of 5 product/contract Written later

ArriVent BioPharma announced the publication of Phase 1b FURTHER trial results for its drug firmonertinib in the journal Cancer Cell, covering patients with EGFR PACC-mutant non-small cell lung cancer. The filing is a clinical data and publication update with no financial results, guidance, or financing terms, so its direct effect on shareholders is not quantified in the filing.

Key points

  • Reported confirmed overall response rates of 43% (160 mg) and 68% (240 mg) in front-line EGFR PACC-mutant NSCLC, per blinded independent central review.
  • Reported 11.1- and 16.0-month median progression-free survival at the two doses.
  • The company continues to enroll patients in its global Phase 3 ALPACCA trial.

The filing

CompanyArriVent BioPharma, Inc. (AVBP)
Form8-K, current report
Filed with the SECOct 19, 2026, 8:08 AM ET
Accession number0001104659-26-116736

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 19, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.